Argus Research Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $550
Portfolio Pulse from Benzinga Newsdesk
Argus Research has maintained its Buy rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and raised the price target from $465 to $550.
June 17, 2024 | 5:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Argus Research has maintained its Buy rating on Vertex Pharmaceuticals and raised the price target from $465 to $550, indicating strong confidence in the company's future performance.
The raised price target from $465 to $550 by Argus Research suggests a positive outlook for Vertex Pharmaceuticals, likely leading to increased investor confidence and a potential short-term price increase.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100